Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Building 10, CRC, 1 East, Rm 3140, Bethesda, Maryland 20892-1109, USA.
Eur J Endocrinol. 2012 Mar;166(3):531-6. doi: 10.1530/EJE-11-0949. Epub 2011 Dec 21.
Spontaneous remission is rare in ectopic ACTH syndrome (EAS). We describe four patients with presumed EAS in whom long-term treatment with steroidogenesis inhibitors was followed by prolonged remission of hypercortisolemia. Biochemical testing was consistent with EAS, but imaging failed to identify a tumor. Patients were treated with ketoconazole alone or with mitotane and/or metyrapone to control hypercortisolemia. Dexamethasone was added when a block and replace strategy was used. Treatment with steroidogenesis inhibitors for 3-10 years in these patients was followed by a prolonged period of remission (15-60 months). During remission, the first patient had an elevated ACTH, low cortisol and 24-h urinary free cortisol (UFC), and adrenal atrophy on computerized tomography scan during remission, suggesting a direct toxic effect on the adrenal glands. Cases 2 and 3 had normal to low ACTH levels and low-normal UFC, consistent with an effect at the level of the ectopic tumor. They did not have a history of cyclicity and case 3 has been in remission for ~5 years, making cyclic Cushing's syndrome less likely. Case 4, with a history of cyclic hypercortisolism, had normal to slightly elevated ACTH levels and low-normal UFC during remission. The most likely etiology of remission is cyclic production of ACTH by the ectopic tumor. Spontaneous and sustained remission of hypercortisolemia is possible in EAS after long-term treatment with steroidogenesis inhibitors; a drug holiday may be warranted during chronic therapy to evaluate this. The pathophysiology remains unclear but may involve several different mechanisms.
自发性缓解在异位 ACTH 综合征(EAS)中很少见。我们描述了 4 例疑似 EAS 的患者,他们长期接受类固醇生成抑制剂治疗后,皮质醇增多症得到了长时间缓解。生化检测符合 EAS,但影像学未能发现肿瘤。患者单独使用酮康唑或联合米托坦和/或美替拉酮治疗以控制皮质醇增多症。当使用阻断和替代策略时,加用地塞米松。这些患者接受类固醇生成抑制剂治疗 3-10 年后,缓解期延长(15-60 个月)。在缓解期间,第 1 例患者的 ACTH 升高、皮质醇和 24 小时尿游离皮质醇(UFC)降低,且在缓解期间 CT 扫描显示肾上腺萎缩,提示对肾上腺有直接毒性作用。第 2 例和第 3 例患者的 ACTH 水平正常或降低,UFC 水平正常或略低,与异位肿瘤水平的作用一致。他们没有周期性病史,第 3 例患者已缓解约 5 年,因此不太可能是周期性库欣综合征。第 4 例患者有周期性皮质醇增多症病史,缓解期间 ACTH 水平正常或略高,UFC 水平正常或略低。缓解的最可能病因是异位肿瘤周期性产生 ACTH。EAS 患者在长期接受类固醇生成抑制剂治疗后,皮质醇增多症可能会自发和持续缓解;在慢性治疗期间,可能需要药物假期来评估这种情况。其病理生理学仍不清楚,但可能涉及几种不同的机制。